1. Home
  2. NAC vs RAPP Comparison

NAC vs RAPP Comparison

Compare NAC & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California Quality Municipal Income Fund

NAC

Nuveen California Quality Municipal Income Fund

HOLD

Current Price

$11.72

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$42.13

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAC
RAPP
Founded
1998
2022
Country
France
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
1998
2024

Fundamental Metrics

Financial Performance
Metric
NAC
RAPP
Price
$11.72
$42.13
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$48.50
AVG Volume (30 Days)
335.6K
381.8K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
4.33%
N/A
EPS Growth
N/A
24.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.94
$13.64
52 Week High
$12.25
$44.28

Technical Indicators

Market Signals
Indicator
NAC
RAPP
Relative Strength Index (RSI) 26.23 55.82
Support Level $11.64 $38.55
Resistance Level $12.04 $43.89
Average True Range (ATR) 0.08 2.72
MACD -0.04 -0.07
Stochastic Oscillator 0.05 60.34

Price Performance

Historical Comparison
NAC
RAPP

About NAC Nuveen California Quality Municipal Income Fund

Nuveen California Quality Municipal Income Fund is a closed-end fixed income mutual fund that prominently invests in tax-exempt municipal bonds from California. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes. Its portfolio mainly includes investment-grade municipal securities of California. The fund targets various sectors such as healthcare, utilities, transportation, and consumer staples.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: